AgenciesNew drugs to fight Alzheimer's disease are released from time to time. Sometimes, the drugs fail and disappoint many people suffering from the disease or their loved ones, who expect the dreaded disease to disappear for good.
Eisai, a Japanese drugmaker, has manufactured a drug named Lecanemab that has been found to reduce slow thinking among patients of Alzheimer's disease.
The results of the findings of this drug's phase 3 clinical trial are yet to be peer reviewed. Still, it has been said, as per media reports, that Lecanemab is a success and has shown a downfall in the number of people going to the doctor for their normal functioning on the global cognitive and functional scale.
The failure of Aduhelm last year, and the disappointment it brought to people with Alzheimer's after a much-touted success rate, shows there is a need for drugs to treat this disease.
Experts have not given a thumbs up to the drug made by Eisai, but Dr. Joanne Pike, president, Alzheimer's Association, has said that the results show a positive development. However, Dr. Alberto Espay, a neurologist at the University of Cincinnati, advised cautious optimism. He felt that the positive effects were still minor.
Around 1,800 patients were kept under observation for 18 months, with researchers monitoring them through a CDR-SB measurement scale. The measurement can quantify the intensity of the disease in people.
Eisai, a Japanese drugmaker, has manufactured a drug named Lecanemab that has been found to reduce slow thinking among patients of Alzheimer's disease.
The results of the findings of this drug's phase 3 clinical trial are yet to be peer reviewed. Still, it has been said, as per media reports, that Lecanemab is a success and has shown a downfall in the number of people going to the doctor for their normal functioning on the global cognitive and functional scale.
The failure of Aduhelm last year, and the disappointment it brought to people with Alzheimer's after a much-touted success rate, shows there is a need for drugs to treat this disease.
Experts have not given a thumbs up to the drug made by Eisai, but Dr. Joanne Pike, president, Alzheimer's Association, has said that the results show a positive development. However, Dr. Alberto Espay, a neurologist at the University of Cincinnati, advised cautious optimism. He felt that the positive effects were still minor.
Around 1,800 patients were kept under observation for 18 months, with researchers monitoring them through a CDR-SB measurement scale. The measurement can quantify the intensity of the disease in people.
FAQs:
- How many people get Alzheimer's?
1 in 9 people suffer from the disease. - How many years can a person live with Alzheimer's?
Average: 4 to 8 years.
Disclaimer Statement: This content is authored by an external agency. The views expressed here are that of the respective authors/ entities and do not represent the views of Economic Times (ET). ET does not guarantee, vouch for or endorse any of its contents nor is responsible for them in any manner whatsoever. Please take all steps necessary to ascertain that any information and content provided is correct, updated, and verified. ET hereby disclaims any and all warranties, express or implied, relating to the report and any content therein.
Read More News on
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
